Business Context and Reporting Period
This Form 8-K Current Report was filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on March 23, 2020. The report details a material definitive agreement entered into on the same date regarding a private placement of securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Units consisting of Common Stock and Warrants.
- Gross Proceeds: Approximately $6.0 million.
- Net Proceeds: Approximately $5.3 million (after placement agent fees and offering expenses).
- Securities Issued:
- 2,675,293 shares of Common Stock.
- Class A Warrants (1-year term) to purchase up to 1,337,659 shares.
- Class B Warrants (5-year term) to purchase up to 2,006,495 shares.
- Offering Price: $2.21425 per Unit to the public; $2.42625 per Unit to directors and executive officers.
- Warrant Exercise Prices:
- Class A: $2.058 (public) and $2.27 (directors/officers).
- Class B: $2.4696 (public) and $2.724 (directors/officers).
Note: This filing does not provide standard financial metrics such as revenue, profit, operating cash flow, or debt levels. It focuses solely on the capital raise transaction.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and the issuance of warrants. The Company intends to use the net proceeds for the following purposes:
- Conducting MicroLine and MicroPine clinical studies.
- Advancing MicroStat's new drug application.
- Working capital and general corporate purposes.
Outlook, Risks, and Contingencies
Registration Rights: The Company entered into a Registration Rights Agreement requiring the filing of a Form S-3 registration statement within 30 days of filing its Form 10-K for the year ended December 31, 2019, to cover the shares issued and underlying the warrants.
Legal Status: The securities were sold in a transaction exempt from registration under Section 4(a)(2) and Regulation D of the Securities Act of 1933. The securities may not be offered or sold absent registration or an applicable exemption.
Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Verify the actual cash balance impact of the $5.3 million net proceeds in the subsequent 10-Q or 10-K filing.
- Confirm the status of the Form S-3 registration statement filing deadline (30 days post-2019 10-K).
- Review the specific terms of the Class A and Class B Warrants in Exhibits 4.1 and 4.2 for anti-dilution provisions.
- Monitor progress on the MicroLine, MicroPine, and MicroStat clinical studies as the primary use of funds.
- Check for any subsequent filings regarding the exercise of warrants or additional dilution.